An Overview of Schizophrenia: Advances in Clinical Considerations, Diagnosis and Treatment

An Overview of Schizophrenia: Advances in Clinical Considerations, Diagnosis and Treatment is organized by Specialty Pharma Education Center (SPEC).

Available Until: 8/15/2022

Accreditation:
Pharmacist continuing education credit
Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2.0 hours (0.20CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Accreditation Period: August 15, 2019 - August 15, 2022

Nursing continuing education credit
Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 2.0 hours of continuing nursing education.

Accreditation Period: August 25, 2019 - August 25, 2021

Learning Objectives:
After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Psychiatric Pharmacists, Psychiatry Nurses and Nurses
• Recognize the prevalence and epidemiology of schizophrenia
• Describe the etiology and pathophysiology of schizophrenia
• Identify the general categories of schizophrenia's symptoms and identify them in patients
• Discuss methods used to diagnose schizophrenia and disorders to be considered in its differential diagnosis
• Describe currently available antipsychotic agents used to treat schizophrenia, their mechanisms of action, efficacy, dosing, safety and tolerability profiles
• Identify common comorbid conditions in patients with schizophrenia
• Recognize the importance of adherence in schizophrenia patients and the prevalence of non-adherence in this patient population